SCHEMBL4586103

SCHEMBL4586103

O=C(CCl)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
EGFR P00533 17/20 1.00
ERBB2 P04626 5/20 1.00
GMPS P49915 2/20 0.57
HDAC6 Q9UBN7 1/20 0.54
ERBB4 Q15303 1/20 0.53
AURKB Q96GD4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30946707 1.00 EGFR (1.00) EGFRERBB2GMPSHDAC6ERBB4
SCHEMBL12494972 0.90 EGFR (0.81) EGFRERBB2HDAC6ERBB4AURKB
SCHEMBL4586538 0.88 EGFR (1.00) EGFRERBB2GMPSHDAC6ERBB4
SCHEMBL12700568 0.85 EGFR (0.74) EGFRERBB2HDAC6ERBB4AURKB
SCHEMBL4587635 0.85 EGFR (0.74) EGFRERBB2HDAC6ERBB4
SCHEMBL12700472 0.85 EGFR (0.77) EGFRERBB2HDAC6ERBB4AURKB
SCHEMBL3240208 0.84 EGFR (1.00) EGFRERBB2
Hydrochloric Acid SCHEMBL8104687 0.83 EGFR (0.70) EGFRERBB2GMPSHDAC6ERBB4
SCHEMBL3248333 0.82 EGFR (0.80) EGFRERBB2ERBB4
SCHEMBL3248334 0.82 EGFR (0.80) EGFRERBB2ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240309327-A1 CARDIOMYOCYTE PRODUCTION METHOD MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-19 US disclosed
EP-4424819-A1 METHOD FOR PRODUCING MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF FUJIFILM Corporation (JP) 2024-09-04 EP disclosed
US-20240277899-A1 PRODUCTION METHOD OF MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF FUJIFILM CORPORATION (JP) 2024-08-22 US disclosed
CN-118159647-A Method for producing cardiomyocyte layer, and use thereof 富士胶片株式会社 2024-06-07 CN disclosed
EP-3431584-B1 METHODS FOR FREEZING AN AGGREGATE OF PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES UNIV KYOTO (JP) 2023-06-28 EP disclosed
WO-2023074783-A1 METHOD FOR PRODUCING MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF 富士フイルム株式会社 2023-05-04 WO disclosed
WO-2023286772-A1 CARDIOMYOCYTE PRODUCTION METHOD 三菱ケミカル株式会社 2023-01-19 WO disclosed
WO-2019175332-A1 BH4 PATHWAY INHIBITION AND USE THEREOF FOR TREATING T-CELL MEDIATED AUTOIMMUNE DISEASES OR HYPERSENSITIVITY IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH (AT) 2019-09-19 WO disclosed
EP-3150705-B1 METHOD FOR INDUCING MYOCARDIAL DIFFERENTIATION OF PLURIPOTENT STEM CELLS USING LOW-MOLECULAR COMPOUND UNIV KYOTO (JP) 2019-05-15 EP disclosed
EP-2966166-B1 PROMOTER OF DIFFERENTIATION OF PLURIPOTENT STEM CELL INTO MYOCARDIUM, WHICH COMPRISES EGF RECEPTOR INHIBITOR UNIV KYOTO (JP) 2019-04-03 EP disclosed
US-20140309246-A1 METHODS AND USE OF BIFUNCTIONAL ENZYME-BUILDING CLAMP-SHAPED MOLECULES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-10-16 US disclosed
EP-2685980-A1 METHODS AND USE OF BIFUNCTIONAL ENZYME-BUILDING CLAMP-SHAPED MOLECULES The Trustees Of The University Of Pennsylvania (US) 2014-01-22 EP disclosed
US-8461166-B2 Anilinoquinazolinyl amide derivatives; radiolabels as bioprobes for Positron Emission Tomography and Single Photon Emission Computed Tomography, and as radiopharmaceuticals for radiotherapy; improved solubility, bioavailability, biostability HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2013-06-11 US disclosed
WO-2012125913-A1 METHODS AND USE OF BIFUNCTIONAL ENZYME-BUILDING CLAMP-SHAPED MOLECULES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-09-20 WO disclosed
WO-2012125913-A1 METHODS AND USE OF BIFUNCTIONAL ENZYME-BUILDING CLAMP-SHAPED MOLECULES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-09-20 WO disclosed
EP-1594504-A4 NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS T K SIGNAL LTD (IL) 2008-12-17 EP disclosed
WO-2006085330-A2 USE OF PROTEIN TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF LEIOMYOMAS HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2006-08-17 WO disclosed
US-20060025430-A1 Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis T.K. SIGNAL LTD. (IL) 2006-02-02 US disclosed
EP-1594504-A2 NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS T.K. Signal Ltd. (IL) 2005-11-16 EP disclosed
WO-2004064718-A2 IRREVERSIBLE INHIBITORS OF EGF RECEPTOR TYROSINE KINASES AND USES THEREOF T.K. SIGNAL LTD. (IL) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309246-A1 METHODS AND USE OF BIFUNCTIONAL ENZYME-BUILDING CLAMP-SHAPED MOLECULES EGFR, JMJD7, ERBB2 EGFR 1/4885ERBB2 3/4885GMPS 2071/4885
US-20240277899-A1 PRODUCTION METHOD OF MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF KIT, MYLK2, TNNT2 EGFR 2160/4885ERBB2 2159/4885GMPS 2089/4885
US-20060025430-A1 Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis EGFR, ERBB2, ERBB3 EGFR 1/4885ERBB2 2/4885GMPS 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.